Abstract:
:Spinal muscular atrophy (SMA) is a rare autosomal recessive neuromuscular disorder most commonly caused by a deletion or mutation in the survival motor neuron 1 (SMN1) gene, which leads to insufficient levels of survival motor neuron (SMN) protein. In such patients, SMN protein production relies on the SMN2 gene. Nusinersen (Spinraza®) is a modified antisense oligonucleotide (ASO) approved in several countries worldwide, including the USA, Japan and those of the EU, for the treatment of 5q SMA. It binds to a specific site in the intron downstream of exon 7 on the SMN2 pre-messenger ribonucleic acid (pre-mRNA), modulating the splicing of SMN2 mRNA and thus increasing the production of SMN protein. In multinational phase III studies, nusinersen (administered intrathecally) provided significant improvements in motor function in patients with infantile- and later-onset 5q SMA compared with a sham procedure. It was also associated with significant improvements in event-free survival and overall survival in patients with infantile-onset 5q SMA, with preliminary data from an ongoing multinational phase II study suggesting a potential clinical benefit with early intervention (i.e. before symptom onset) with nusinersen. Preliminary subgroup data from a phase III extension study suggested continued improvements in motor function with longer-term therapy. Nusinersen demonstrated a favourable safety profile in clinical studies in symptomatic and presymptomatic patients, with no safety concerns due to nusinersen exposure. In conclusion, although studies in presymptomatic patients and over the long term in symptomatic patients are ongoing, current evidence indicates that nusinersen modifies 5q SMA and has a favourable safety profile and, thus, is a valuable treatment for this patient population.
journal_name
CNS Drugsjournal_title
CNS drugsauthors
Hoy SMdoi
10.1007/s40263-018-0545-1subject
Has Abstractpub_date
2018-07-01 00:00:00pages
689-696issue
7eissn
1172-7047issn
1179-1934pii
10.1007/s40263-018-0545-1journal_volume
32pub_type
杂志文章,评审相关文献
CNS DRUGS文献大全abstract::Since 1989, several novel antipsychotic drugs have become available for use including clozapine, risperidone, olanzapine, quetiapine and ziprasidone. These agents represent a substantial improvement in the treatment of schizophrenia and related disorders and are considered to have a favourable adverse effect profile r...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/00023210-200317050-00002
更新日期:2003-01-01 00:00:00
abstract::Alcoholic patients suffer from harmful allostatic neuroplastic changes in the brain causing an acute withdrawal syndrome upon cessation of drinking followed by a protracted abstinence syndrome and an increased risk of relapse to heavy drinking. Benzodiazepines have long been the treatment of choice for detoxifying pat...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-015-0240-4
更新日期:2015-04-01 00:00:00
abstract::Bipolar depression is the predominant abnormal mood state in bipolar disorder. However, despite the key pertinence of this phase of the condition, the focus of research and indeed of clinical interest in the management of bipolar disorder has been mainly on mania. Bipolar depression has been largely neglected, and ear...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/00023210-200317010-00002
更新日期:2003-01-01 00:00:00
abstract::Narcolepsy type 1 and narcolepsy type 2 are central disorders of hypersomnolence. Narcolepsy type 1 is characterized by excessive daytime sleepiness and cataplexy and is associated with hypocretin-1 deficiency. On the other hand, in narcolepsy type 2, cerebrospinal fluid hypocretin-1 levels are normal and cataplexy ab...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-016-0337-4
更新日期:2016-05-01 00:00:00
abstract::Multiple sclerosis (MS) has a profound impact on health-related quality of life (HRQoL), a comprehensive subjective measure of the patient's health status. Assessment of HRQoL informs on the potential advantages and disadvantages of disease-modifying drugs (DMDs) beyond their effects on observer-based disability and m...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-017-0444-x
更新日期:2017-07-01 00:00:00
abstract::Duloxetine (Cymbalta(R)) is a potent serotonin and noradrenaline (norepinephrine) reuptake inhibitor (SNRI) in the CNS. It is indicated for the treatment of generalized anxiety disorder (GAD) as well as other indications. In patients with GAD of at least moderate severity, oral duloxetine 60-120 mg once daily was effe...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/00023210-200923060-00006
更新日期:2009-01-01 00:00:00
abstract::Nucleoside analogue reverse transcriptase inhibitors (NRTIs), used as part of highly active antiretroviral therapy for the treatment of HIV and AIDS, disrupt neuronal mitochondrial DNA synthesis, resulting in antiretroviral toxic neuropathy (ATN). Acetyl-L-carnitine (ALC) enhances neurotrophic support of sensory neuro...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/00023210-200721001-00004
更新日期:2007-01-01 00:00:00
abstract::Sodium channel blockers have been the mainstay of the pharmacological management of focal and generalised tonic-clonic seizures for more than 70 years. The focus of this paper will be on phenytoin, carbamazepine, lamotrigine, oxcarbazepine, rufinamide, lacosamide and eslicarbazepine acetate. All these antiepileptic dr...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-017-0441-0
更新日期:2017-07-01 00:00:00
abstract::Multiple stimulant and non-stimulant medications are approved for the treatment of attention-deficit/hyperactivity disorder (ADHD), one of the most prevalent childhood neurodevelopmental disorders. Choosing among the available agents and determining the most effective ADHD medication for a given child can be a time-co...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-020-00702-y
更新日期:2020-04-01 00:00:00
abstract::The kynurenine pathway constitutes the main route of tryptophan degradation and generates the production of several neuroactive compounds; quinolinic acid is an excitotoxic NMDA receptor agonist, 3-hydroxykynurenine is a free-radical generator and kynurenic acid (KYNA) is an antagonist at glutamate and nicotinic recep...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/00023210-200923020-00001
更新日期:2009-01-01 00:00:00
abstract:BACKGROUND:The molecules that provide access to activated T cells in the CNS, including chemokines, have been considered to be a crucial step in the pathogenesis of multiple sclerosis (MS). AIMS:In this study, we investigated serial serum chemokine levels in patients with relapsing-remitting MS over 1 year and the ass...
journal_title:CNS drugs
pub_type: 杂志文章
doi:10.2165/11595060-000000000-00000
更新日期:2011-11-01 00:00:00
abstract::Frontotemporal lobar degeneration (FTLD) describes a spectrum of clinically, pathologically and genetically heterogeneous neurodegenerative disorders of unknown aetiology. FTLD spectrum disorders collectively represent a leading cause of early-onset dementia, with most cases presenting between 45 and 64 years of age. ...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/11640070-000000000-00000
更新日期:2012-10-01 00:00:00
abstract:BACKGROUND:Earlier commencement of clozapine has been related to a better response in treatment-resistant schizophrenia. OBJECTIVES:To identify variables that predict clozapine use after a first episode of schizophrenia (FES). METHODS:Patients with FES and ≤15 days of lifetime antipsychotic treatment were followed up...
journal_title:CNS drugs
pub_type: 杂志文章
doi:10.1007/s40263-016-0358-z
更新日期:2016-10-01 00:00:00
abstract::There have been significant developments in the understanding of depression in children and adolescents in the past few years, including an increased recognition that significant depressive illness occurs in this patient group. Pharmacological and psychotherapeutic treatments are used to manage depression in children ...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/00023210-200620010-00001
更新日期:2006-01-01 00:00:00
abstract::Bulimia nervosa is an eating disorder characterised by recurrent episodes of binge eating and associated efforts to purge the ingested calories through self-induced vomiting, laxative or diuretic abuse, fasting or intensive exercise. The aetiopathogenesis and pathophysiology of the disorder are currently unclear. Biol...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/00023210-200115020-00004
更新日期:2001-01-01 00:00:00
abstract::gamma-Aminobutyric acid (GABA) is considered to be the major inhibitory neurotransmitter in the brain and loss of GABA inhibition has been clearly implicated in epileptogenesis. GABA interacts with 3 types of receptor: GABAA, GABAB and GABAC. The GABAA receptor has provided an excellent target for the development of d...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/00023210-200115050-00001
更新日期:2001-01-01 00:00:00
abstract::Tramadol-an atypical opioid analgesic-has a unique pharmacokinetic and pharmacodynamic profile, with opioidergic, noradrenergic, and serotonergic actions. Tramadol has long been used as a well-tolerated alternative to other drugs in moderate pain because of its opioidergic and monoaminergic activities. However, cumula...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-019-00623-5
更新日期:2019-05-01 00:00:00
abstract::The original article can be found online. ...
journal_title:CNS drugs
pub_type: 杂志文章,已发布勘误
doi:10.1007/s40263-018-0561-1
更新日期:2018-09-01 00:00:00
abstract::It is difficult to determine the relative efficacy of atypical antipsychotics for the treatment of schizophrenia, based on the available literature. The purpose of this article is to review and compare the efficacy of two atypical antipsychotics: olanzapine and ziprasidone.This review focused on randomised trials in w...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/00023210-200519060-00003
更新日期:2005-01-01 00:00:00
abstract:BACKGROUND:Cenobamate is a novel tetrazole-derived carbamate compound with a dual mechanism of action. This drug can enhance the inactivated state of voltage-gated sodium channels, preferentially inhibiting the persistent component of the sodium channel current, and acts as a positive allosteric modulator of GABAA rece...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-020-00759-9
更新日期:2020-11-01 00:00:00
abstract:INTRODUCTION:Intranasal (IN) insulin acutely improves verbal memory in mild cognitive impairment (MCI)/Alzheimer's disease (AD), but its therapeutic effects may be attenuated in apolipoprotein E4 (ApoE4) carriers. Furthermore, rapid-acting (RA) insulins may have superior therapeutic effects compared with regular insuli...
journal_title:CNS drugs
pub_type: 杂志文章,随机对照试验
doi:10.1007/s40263-014-0214-y
更新日期:2014-12-01 00:00:00
abstract::Mitoxantrone (Novantrone), a synthetic anthracenedione derivative, is an antineoplastic, immunomodulatory agent. Its presumed mechanism of action in patients with multiple sclerosis (MS) is via immunomodulatory mechanisms, although these remain to be fully elucidated. Intravenous mitoxantrone treatment improved neurol...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/00023210-200418060-00010
更新日期:2004-01-01 00:00:00
abstract:PURPOSE:To monitor weight regain after therapy discontinuation in patients with migraine experiencing weight loss during topiramate (TPM) treatment. METHODS:Patients with migraine without aura were enrolled in this observational prospective study. Weight, body mass index (BMI), waist circumference, systolic and diasto...
journal_title:CNS drugs
pub_type: 杂志文章
doi:10.1007/s40263-015-0229-z
更新日期:2015-02-01 00:00:00
abstract:INTRODUCTION:Cognitive impairment is prevalent and debilitating among persons with multiple sclerosis (MS). While many pharmacologic treatments have shown good efficacy in reducing clinical relapses, brain lesions, and improving certain physical symptoms, their efficacy for improving cognitive function is not well unde...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-020-00734-4
更新日期:2020-06-01 00:00:00
abstract::The link between diabetes mellitus and Alzheimer's disease (AD) has been known for the last few decades. Since insulin and insulin receptors are known to be present in the brain, the downstream signalling as well as the effect of hyperinsulinemia have been extensively studied in both AD and Parkinson's disease. Glucag...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-015-0301-8
更新日期:2015-12-01 00:00:00
abstract::▴ Ziprasidone is a novel antipsychotic drug. It has high affinity for serotonin 5-HT(2) and dopamine D(2) receptors in vitro, with an 11-fold higher affinity for 5-HT(2) than for D(2) receptors, suggestive of a low potential for inducing motor disturbance [including extrapyramidal symptoms (EPS)].▴ The effects of zipr...
journal_title:CNS drugs
pub_type: 杂志文章
doi:10.2165/00023210-199708020-00006
更新日期:1997-08-01 00:00:00
abstract::Anticonvulsant hypersensitivity syndrome (AHS) is a rare, but potentially fatal, adverse reaction that occurs in patients, including children, who are treated with anticonvulsants. During metabolism of the anticonvulsant, toxic arene-oxide compounds are produced. AHS is associated with both cutaneous and systemic symp...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/00023210-200216030-00006
更新日期:2002-01-01 00:00:00
abstract:OBJECTIVE:Many authors have reported discontinuation symptoms associated with selective serotonin reuptake inhibitors (SSRIs). The aim of this study was to investigate the incidence and characteristics of the discontinuation syndrome in patients who stopped treatment with the SSRIs paroxetine and fluoxetine under the u...
journal_title:CNS drugs
pub_type: 临床试验,杂志文章
doi:10.2165/00023210-200216040-00006
更新日期:2002-01-01 00:00:00
abstract::Infections are common in people with dementia, and antibiotic use is widespread, albeit highly variable, across healthcare settings and countries. The few studies conducted to date that consider the appropriateness of antibiotic prescribing specifically for people with dementia focus on people with advanced dementia a...
journal_title:CNS drugs
pub_type: 杂志文章
doi:10.1007/s40263-017-0427-y
更新日期:2017-06-01 00:00:00
abstract::This article reviews the conceptual progression in the pharmacological therapy of malignant astrocytoma (MA) over the past decade, and its future trends. It is a selective rather than an exhaustive inventory of literature citations. The experience of the Brain Tumour Cooperative Group (BTCG) and earlier phase III tria...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/00023210-200115090-00005
更新日期:2001-01-01 00:00:00